Dr. Rasha El Sherif MD, Consultant of Neuromuscular disorders
Dr. Rasha has been in the field of Neuromuscular Genetics for 20 years and has been working to apply the highest standards of care for muscles disease in Egypt.
After graduating from medical school, Ain Shams University, Dr. Rasha El Sherif travelled to NCNP, Tokyo, Japan in 1998 to start her training on the genetic diagnosis of neuromuscular disorders. In 2000 she started under supervision of Pro. Etribi the first to Neurogenetics lab, Neurology Department for diagnosis of neuromuscular disorders in Egypt.
In 2008 she submitted her Doctorate degree thesis” Dystrophin gene analysis in Egyptian patients” which was supervised by Dr. Ikuya Nonaka and Dr. Ichizo Nishino, NCNP, Japan.
In 2006, she received an Award from Ain Shams University for her research work in diagnosis of neuromuscular disorders in Egypt.
In 2013, she became the coordinator of the Egyptian Neuromuscular Registry through TREAT-NMD after receiving a training in the Newcastle office for TREAT-NMD, UK.
In 2015, she was nominated as the president of the First Egyptian International Neuromuscular conference. http://www.treat-nmd.eu/events/556/.
In 2017, Dr. Rasha was elected as the medical consultant for the First Egyptian Muscular Dystrophy Patient Society, which was founded in partnership with the Egyptian Neuromuscular registry.
Director of MYO-CARE Neuromuscular Centre, Cairo Egypt.
Since 2010 till that moment, she has been working as a consultant of Neuromuscular disorders and Director of Neuromuscular Unit, Egypt air hospital in Cairo, Egypt.
She coordinated medical convoys in different cities in Egypt: Aswan, Minia, Menoufia and Suez to help in diagnosis of patients and raising awareness for the importance of applying high standards of care among doctors.
The Egyptian Neuromuscular Registry has been active since 2013 voluntarily to set a database for the NMD in Egypt.
What is the registry?
A patient registry collects information about patients who are affected by a certain NMD.
As many therapies for NMD became FDA approved (DMD-SMA-ALS) it became mandatory that eligible patients can be found and contacted quickly. The best way for this to happen is through a database or “registry” that contains all the information about their disease needed by the health officials.
Scientific advances over recent years have led to substantial changes in the treatment of many neuromuscular diseases. Several new therapeutic strategies which target specific genetic defects are being developed. Some of these treatments already have plans in place for large studies involving patients from more than one country.
For the country to provide therapies information about number of patients and clinical status need to be known.
That is why setting a database for NMD is extremely important.
All information is stored in Egypt in confidential software.
Any doctor can add his patients.
Dr. Rasha El Sherif
Dr. May Gamal
Toaa El Samahy
Ain Shams University graduate
IT specialist, responsible for patient data entry.
Ain Shams University graduate
Egyptian Neuromuscular Registry
Our team is waiting for any inquiries and we will get back to you ASAP.